Stockreport

IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two

IGC Pharma, Inc.  (IGC) 
NASDAQ:AMEX Investor Relations: igcinc.us/investor-center/overview
PDF - Study Achieves Secondary End Point: Demonstrates Clinical Reduction, approaching statistical significance, at Week Two, in Agitation in Dementia due to Alzheimer’s - [Read more]